P-FLUOROFENTANYL HYDROCHLORIDE

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H27FN2O.ClH
Molecular Weight	390.922
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of P-FLUOROFENTANYL HYDROCHLORIDE

Structure Search

SMILES

Cl.CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=C(F)C=C3

InChI

InChIKey=CTXOPDVNXMUJCV-UHFFFAOYSA-N

InChI=1S/C22H27FN2O.ClH/c1-2-22(26)25(20-10-8-19(23)9-11-20)21-13-16-24(17-14-21)15-12-18-6-4-3-5-7-18;/h3-11,21H,2,12-17H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	C22H27FN2O
Molecular Weight	354.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10945855 | https://www.ncbi.nlm.nih.gov/pubmed/12615244

Parafluorofentanyl is a selective mu-opioid agonist, an analog of fentanyl, developed by Janssen. The drug was not developed for human use but is produced and abused illegally.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10945855	Agonist 2752		4.2 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2907025	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Development of an enzyme-linked immunosorbent assay for fentanyl and applications of fentanyl antibody-coated nanoparticles for sample preparation.	2006-06-16	16621415

Patents

Sample Use Guides

In Vivo Use Guide

On a black market, parafluorofentanyl is distributed in form of capsules and tablets containing the drug in the range of 33.8-408.7 ug. In preclinical studies parafluorofentanyl was administered to rats subcutaneously.

Route of Administration: Other

In Vitro Use Guide

The potency of parafluorofentanyl with respect to cloned hMOR was investigated using the heterologous expression in X. laevis. Receptor subtype was individually coexpressed with GIRK1/GIRK2 channels and RGS4, mimicking the native neuronal G protein-mediated pathway of K1 channel activation. The two-microelectrode voltage-clamp technique was then used to measure the opioid receptor-activated GIRK1/GIRK2 channel response as the increase of the inward K1 current at 270 mV, evoked by the application of increasing concentrations of opioid ligands. Parafluorofentanyl activated hMOR with EC50 of 4.2 nM.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:26:38 GMT 2025` Edited by `admin` on `Tue Apr 01 16:26:38 GMT 2025`
Record UNII	VP0NU00C3G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

P-FLUOROFENTANYL HYDROCHLORIDE

Common Name

English

NIH-10491

Preferred Name

English

PROPANAMIDE, N-(4-FLUOROPHENYL)-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)-, MONOHYDROCHLORIDE

Common Name

English

PROPANAMIDE, N-(4-FLUOROPHENYL)-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

PARA-FLUOROFENTANYL HYDROCHLORIDE

Common Name

English

PARA-FLUOROFENTANYL HYDROCHLORIDE SALT

Common Name

English

Code System Code Type Description

FDA UNII

VP0NU00C3G